Copyright
©The Author(s) 2025.
World J Clin Cases. Apr 6, 2025; 13(10): 100223
Published online Apr 6, 2025. doi: 10.12998/wjcc.v13.i10.100223
Published online Apr 6, 2025. doi: 10.12998/wjcc.v13.i10.100223
Table 1 Beta thalassemia variants
| Type of β-globin gene variant | Subtype of β-globin gene variant | Beta-thalassemia severity type | |
| Point mutations | Trancriptional variants | Promoter regulatory elements; 5’ untranslated regions | β+ or β++ |
| Variants involving RNA processing | Splice junction; consensus splice sites; cryptic splice sites; RNA cleavage - poly A signal; others in 3’ untranslated regions | β0, β+ or β++ | |
| Variants involving RNA translation | Initiation codon; nonsense codons; frameshift | β0 | |
| Deletions | β0 | ||
Table 2 Available therapy for transfusion-dependent beta thalassemia
| Treatment | Mode of action |
| Red blood cell transfusion | Correction of anemia |
| Deferoxamine | Iron chelation |
| Deferiprone | |
| Deferasirox | |
| Hematopoietic stem cell transplantation | Replacement with healthy hematopoietic stem cells |
| Luspatercept | Late-stage erythroid maturation |
| Exagamglogene autotemcel and lovotibeglogene autotemcel | Autologous genome-modifying/editing based therapy |
- Citation: Dordevic A, Mrakovcic-Sutic I, Pavlovic S, Ugrin M, Roganovic J. Beta thalassemia syndromes: New insights. World J Clin Cases 2025; 13(10): 100223
- URL: https://www.wjgnet.com/2307-8960/full/v13/i10/100223.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v13.i10.100223
